Cytek Biosciences Inc., a Fremont, Calif.-based provider of cell analysis instrumentation and solutions, closed a $120m Series D funding round.
The round was co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. Additionally, RA Capital and Hillhouse Capital have joined Cytek’s board of directors.
The company intends to use the funds to expand its global infrastructure, sustain growth and deliver on its technology platform to offer expanded support for key areas of study such as immunotherapy, immuno-oncology and infectious diseases such as COVID-19.
Led by Dr. Wenbin Jiang, CEO, Cytek Biosciences is a flow cytometry solution provider that develops compact, affordable instruments with high multiplexing capability and a wide range of services to support scientists and clinicians. The company also offers proprietary cFluor™ reagents, which ensure optimal performance for users of its instruments in a multicolor environment.